Kymera Therapeutics Appoints Brian Adams as New Chief Legal Officer and Corporate Secretary

Kymera Therapeutics has appointed Brian Adams as its new Chief Legal Officer and Corporate Secretary. Adams brings nearly 20 years of experience from notable companies like Relay Therapeutics and Genzyme Corporation. He succeeds Ellen Chiniara, who is retiring to pursue board service and advisory roles. Adams will lead the company's legal, governance, and intellectual property functions, and his expertise is expected to advance Kymera's novel programs through clinical development and commercialization.

Kymera Therapeutics, Inc. has announced the appointment of Brian Adams as its new Chief Legal Officer and Corporate Secretary. Adams brings nearly two decades of experience from notable companies such as Relay Therapeutics and Genzyme Corporation. He succeeds Ellen Chiniara, who is retiring to focus on board service and advisory roles. Adams will lead the company's legal, governance, and intellectual property functions, and his expertise is expected to advance Kymera's novel programs through clinical development and commercialization [1][2].

Adams is a highly accomplished legal executive with a background spanning corporate development, strategic planning, and governance. Prior to joining Kymera, he served as Chief Legal Officer of Relay Therapeutics, responsible for leading all aspects of Relay’s legal and compliance operations. Before Relay, he held senior roles at Keryx Biopharmaceuticals, Algeta ASA, AVEO Oncology, and Genzyme Corporation. Additionally, he practiced at Bingham McCutchen LLP, advising private equity sponsors, biotechs, and other emerging technology companies on a broad range of corporate matters and financing transactions. Adams holds a B.A. from Harvard University and a J.D. from the Catholic University of America’s Columbus School of Law.

Kymera Therapeutics is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. The company is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions [2].

The appointment of Brian Adams signals a strategic move for Kymera as it continues to grow and scale its novel programs. His proven leadership and deep expertise in the life sciences are expected to be instrumental in advancing Kymera's mission to transform care for millions of patients living with immuno-inflammatory diseases.

References:
[1] https://www.marketscreener.com/news/kymera-therapeutics-inc-appoints-brian-adams-as-chief-legal-officer-and-corporate-secretary-ce7d59dbdd8df227
[2] https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-appoints-brian-adams-chief-legal-officer-and